Berapa banyak dividen yang dibayarkan Ligand Pharmaceuticals 2025?
Berdasarkan data terkini dari Februari 2025, Ligand Pharmaceuticals telah membayar dividen sejumlah total 5,04 USD per saham dalam 12 bulan terakhir. Dengan kurs Ligand Pharmaceuticals saat ini sebesar 120,00 USD, ini setara dengan yield dividen sebesar 4,20 %.
Dividen dibayarkan sebanyak kali per tahun.
12,50 % Dividen Yield | = | 15,00 USD Dividen | 120,00 USD Harga Saham |
|
Apakah dividen Ligand Pharmaceuticals aman?
Ligand Pharmaceuticals meningkatkan dividen sejak 2 tahun.
Dalam kurun waktu 10 tahun terakhir, Ligand Pharmaceuticals telah diturunkan sebesar 0 % setiap tahunnya.
Dalam kurun waktu 5 tahun, turun pembagian dividen meningkat sebesar 0 %.
Analis memperkirakan untuk tahun fiskal yang sedang berjalan akan terjadi pertumbuhan sebesar Pengurangan dividen%.
Ligand Pharmaceuticals Aktienanalyse
Apa yang dilakukan Ligand Pharmaceuticals?
Ligand Pharmaceuticals Inc is an American company that has been operating in the biotechnology industry for over 30 years. It was founded in 1987 in San Diego, California and has since built an impressive track record.
The business model of Ligand Pharmaceuticals Inc is based on the development and commercialization of innovative drugs and technologies for the pharmaceutical and biotechnology industry. The company is a leading provider of resources for drug discovery and development, including ligand design, synthesis and analysis, tools for drug screening, and technologies for therapy optimization.
Ligand Pharmaceuticals Inc is divided into several business segments that focus on different industries and categories of medication. These include oncology, immunology, neurology, metabolic diseases, and rare diseases.
One of the key areas of Ligand Pharmaceuticals Inc is oncology, which focuses on the development of cancer drugs. The company currently has several innovative drugs in the pipeline targeting various types of cancer and showing promising results in clinical trials.
Another important area of Ligand Pharmaceuticals Inc is immunology, which focuses on the development of drugs for autoimmune diseases. The company has some promising partnerships in this field, including one with Bristol Myers Squibb for the joint development of antibodies against the CTLA-4 receptor.
In addition to drug development, Ligand Pharmaceuticals Inc also offers various technologies and tools for drug screening and therapy optimization. These include platforms for antibody and small molecule discovery, as well as technologies for antibody manufacturing and genome editing.
Another important aspect of Ligand Pharmaceuticals Inc's business model is its partnership with other pharmaceutical companies. The company heavily relies on collaboration and currently has several strategic partnerships with some of the world's largest pharmaceutical companies. These partnerships allow Ligand to provide its partners with access to its technology and drug candidates, thereby expanding its portfolio.
Over the years, Ligand Pharmaceuticals Inc has brought many successful products and technologies to the market. Some of the most well-known and successful products include Kyprolis, a treatment for multiple myeloma, and Promacta, a medication for immune thrombocytopenia.
Overall, Ligand Pharmaceuticals Inc has built an impressive track record and is now considered one of the leading providers of resources for drug discovery and development. The company continues to prioritize collaboration and innovation and will undoubtedly bring many more innovative products and technologies to the market in the future. Ligand Pharmaceuticals adalah salah satu perusahaan paling populer di Eulerpool.com.Rencana tabungan saham menawarkan kesempatan menarik bagi investor untuk membangun kekayaan jangka panjang. Salah satu keuntungan utamanya adalah efek rata-rata biaya: Dengan berinvestasi dalam jumlah tetap secara reguler ke dalam saham atau dana saham, otomatis anda akan membeli lebih banyak saham ketika harga rendah, dan lebih sedikit ketika harga tinggi. Hal ini dapat menghasilkan harga rata-rata per saham yang lebih menguntungkan seiring waktu. Selain itu, rencana tabungan saham juga memungkinkan investor kecil untuk mengakses saham-saham mahal, karena mereka dapat berpartisipasi dengan jumlah yang kecil. Investasi rutin juga mendukung strategi investasi yang disiplin dan membantu menghindari keputusan emosional, seperti membeli atau menjual secara impulsif. Di samping itu, investor juga mendapat manfaat dari potensi peningkatan nilai saham serta dari pembagian dividen, yang bisa direinvestasikan, meningkatkan efek bunga majemuk dan dengan demikian pertumbuhan dari modal yang diinvestasikan.